Shire Gains Favorable Ruling on US Patent for Ulcerative Colitis Drug
Shire has received a favorable ruling from the US Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB), which issued their decision upholding the validity of US Patent No. 6,773,720, related to Shire’s Lialda (mesalamine), a once-daily product indicated for both the induction of remission of mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.
A petition seeking to institute inter partes review was filed with the US Patent and Trademark Office’s PTAB in April of 2015 by the Coalition For Affordable Drugs II LLC Fund. The PTAB found that the patent was valid in light of the challenges put forward by the petitioner.